Executive Vice President, General Counsel · Horizon Therapeutics Public Ltd Co (HZNP)

Sean Clayton

FY2022 is the first fiscal year CompBrief holds for Sean Clayton as a named executive officer of Horizon Therapeutics Public; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$10,872,207

Salary $547,685Stock awards $3,839,414Bonus $6,382,699

2nd of 6 named executive officers at Horizon Therapeutics Public by FY2022 total.

6 named officers on file for Horizon Therapeutics Public, FY2022

Sean Clayton’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 1 equity grant, each cited to its filing
  • HZNP’s disclosed peer group of 13 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Horizon Therapeutics Public’s whole pay program stands against its peers

  • Horizon Therapeutics Public’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on HZNP→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed June 30, 2023 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Sean Clayton’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Sean Clayton compensation by year

Horizon Therapeutics Public Summary Compensation Table · the one fiscal year held
In US dollars, as Horizon Therapeutics Public reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022
Salary$547,685
Bonus$6,382,699
Stock awards$3,839,414
Option awards$0
Non-equity incentive$0
Pension and deferred compensation$0
All other$102,409
Total$10,872,207

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Horizon Therapeutics Public Ltd Co DEF 14A filed June 30, 2023, accession 0001193125-23-180318, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Horizon Therapeutics Public Ltd Co filed document, accession 0001193125-23-180318. Every figure is read from that document and cited to the page and table it appears in. Filed June 30, 2023.

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
RSU42,387$4,823,641—

Per the Outstanding Equity Awards at Fiscal Year-End table in Horizon Therapeutics Public Ltd Co's FY2022 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

7 Form 4 lines since the FY2022 proxy (filed June 30, 2023)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2023-10-06Disposition to the issuer—7,655$116.500
2023-10-06Disposition to the issuer—745$116.500
2023-10-06Disposition to the issuer derivative—28,258—0
2023-10-06Disposition to the issuer derivative—22,997—0
2023-10-06Disposition to the issuer derivative—5,749—0
2023-10-06Disposition to the issuer derivative—5,749—0
2023-10-06Disposition to the issuer derivative—11,499—0

The 7 most recent of 7 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Horizon Therapeutics Public’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Timothy WalbertChairman, President and Chief Executive Officer$20,103,869
Sean Clayton · this pageExecutive Vice President, General Counsel$10,872,207
Elizabeth ThompsonExecutive Vice President, Research and Development$8,481,020
Aaron CoxExecutive Vice President, Chief Financial Officer$7,174,543
Andy PasternakExecutive Vice President, Chief Strategy Officer$6,752,794
Paul HoelscherFormer Executive Vice President, Chief Financial Officer$1,822,581

The full Horizon Therapeutics Public compensation record

free company brief

This page is one person within Horizon Therapeutics Public's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Horizon Therapeutics Public proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Horizon Therapeutics Public's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Sean Clayton's compensation dossier · One-time report. No refunds.